Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organon & Co.OGN · Entity 4115 | Gen. Counsel & Corp. Secy. | March 31, 2026 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organon & Co.
Report date March 31, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 92,639.163 |
Ending reported balance
After 2026-03-31 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-03-31 · Exercise / conversion · Acquired 6,201 · Balance 85,602.163 Row 2 · 2026-03-31 · Tax withholding · Disposed 1,767 · Balance 83,835.163 F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were granted. Row 3 · 2026-03-31 · Exercise / conversion · Acquired 12,312 · Balance 96,147.163 Row 4 · 2026-03-31 · Tax withholding · Disposed 3,508 · Balance 92,639.163 F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were granted. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 183,639 |
Reported balance
After 2026-03-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-31 · Grant · Acquired 183,639 · Balance 183,639 F2: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-31 · Exercise / conversion · Disposed 6,201 · Balance 0 F3: Each RSU represents a contingent right to receive one share of Organon common stock. F4: On March 31, 2023, the Reporting Person was granted 18,600 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 24,625 |
Reported balance
After 2026-03-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-31 · Exercise / conversion · Disposed 12,312 · Balance 24,625 F3: Each RSU represents a contingent right to receive one share of Organon common stock. F5: On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were granted.
F2: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
F3: Each RSU represents a contingent right to receive one share of Organon common stock.
F4: On March 31, 2023, the Reporting Person was granted 18,600 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.
F5: On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2023 Filed May 3, 2023 19:09 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted stock units · Derivative | 1,099 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027177 · doc4.xml · derivative · entry 3 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,099 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:09 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 314 | $24.63 | $7,733.82 |
DisclosureSEC source: 0001209191-23-027177 · doc4.xml · nonDerivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,570 Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:09 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 1,099 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-027177 · doc4.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:21 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 66,793 | $0.00 Strike: $23.52 | $0.00 |
DisclosureSEC source: 0001209191-23-023089 · doc4.xml · derivative · entry 4 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,793 Underlying: Common Stock · 66,793 shares Expires 2033-03-31 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:21 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 7,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023089 · doc4.xml · derivative · entry 3 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,838 Underlying: Common Stock · 7,419 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. F2 · derivative.expiration_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:21 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 2,115 | $23.09 | $48,835.35 |
DisclosureSEC source: 0001209191-23-023089 · doc4.xml · nonDerivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,785 Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:21 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 7,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023089 · doc4.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 17:40 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 4,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014878 · doc4.xml · derivative · entry 3 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,616 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As originally reported on the Form 3, dated January 10, 2023, these Restricted Stock Units vested on December 31, 2022. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2023. F2 · derivative.exercise_date: As originally reported on the Form 3, dated January 10, 2023, these Restricted Stock Units vested on December 31, 2022. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2023. F2 · derivative.expiration_date: As originally reported on the Form 3, dated January 10, 2023, these Restricted Stock Units vested on December 31, 2022. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2023. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 17:40 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,431 | $25.09 | $35,903.79 |
DisclosureSEC source: 0001209191-23-014878 · doc4.xml · nonDerivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,481 Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 17:40 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 4,616 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014878 · doc4.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.